Dicerna Pharmaceuticals Competitors

Mirati Therapeutics (NASDAQ:MRTX) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk and Volatility

Mirati Therapeutics has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Earnings & Valuation

This table compares Mirati Therapeutics and Dicerna Pharmaceuticals' top-line revenue, earnings per share and valuation.

Dicerna Pharmaceuticals has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

94.9% of Mirati Therapeutics shares are held by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 4.1% of Mirati Therapeutics shares are held by insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Mirati Therapeutics and Dicerna Pharmaceuticals, as provided by MarketBeat.

Mirati Therapeutics presently has a consensus price target of $218.5714, suggesting a potential upside of 37.21%. Dicerna Pharmaceuticals has a consensus price target of $39.1429, suggesting a potential upside of 33.46%. Given Mirati Therapeutics' higher probable upside, equities analysts clearly believe Mirati Therapeutics is more favorable than Dicerna Pharmaceuticals.

Profitability

This table compares Mirati Therapeutics and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

BridgeBio Pharma (NASDAQ:BBIO) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Valuation and Earnings

This table compares BridgeBio Pharma and Dicerna Pharmaceuticals' gross revenue, earnings per share and valuation.

Dicerna Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BridgeBio Pharma and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

95.5% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. 40.3% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for BridgeBio Pharma and Dicerna Pharmaceuticals, as reported by MarketBeat.

BridgeBio Pharma presently has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Dicerna Pharmaceuticals has a consensus target price of $39.1429, indicating a potential upside of 33.46%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Dicerna Pharmaceuticals is more favorable than BridgeBio Pharma.

Risk and Volatility

BridgeBio Pharma has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Valuation & Earnings

This table compares Dicerna Pharmaceuticals and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Dicerna Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dicerna Pharmaceuticals and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Volatility & Risk

Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.

Insider & Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Dicerna Pharmaceuticals and Ultragenyx Pharmaceutical, as provided by MarketBeat.

Dicerna Pharmaceuticals presently has a consensus price target of $39.1429, indicating a potential upside of 33.46%. Ultragenyx Pharmaceutical has a consensus price target of $131.20, indicating a potential upside of 20.73%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Dicerna Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Summary

Dicerna Pharmaceuticals beats Ultragenyx Pharmaceutical on 10 of the 14 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Profitability

This table compares Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals, as provided by MarketBeat.com.

Dicerna Pharmaceuticals presently has a consensus price target of $39.1429, indicating a potential upside of 33.46%. Arrowhead Pharmaceuticals has a consensus price target of $85.3077, indicating a potential upside of 26.27%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Dicerna Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals' top-line revenue, earnings per share and valuation.

Arrowhead Pharmaceuticals has higher revenue and earnings than Dicerna Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GW Pharmaceuticals (NASDAQ:GWPH) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for GW Pharmaceuticals and Dicerna Pharmaceuticals, as reported by MarketBeat.

GW Pharmaceuticals currently has a consensus target price of $204.0909, indicating a potential downside of 6.69%. Dicerna Pharmaceuticals has a consensus target price of $39.1429, indicating a potential upside of 33.46%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Dicerna Pharmaceuticals is more favorable than GW Pharmaceuticals.

Insider and Institutional Ownership

81.0% of GW Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. 3.1% of GW Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares GW Pharmaceuticals and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

GW Pharmaceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares GW Pharmaceuticals and Dicerna Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

GW Pharmaceuticals has higher revenue and earnings than Dicerna Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

GW Pharmaceuticals beats Dicerna Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Dicerna Pharmaceuticals and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and Ascendis Pharma A/S's gross revenue, earnings per share (EPS) and valuation.

Dicerna Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Dicerna Pharmaceuticals and Ascendis Pharma A/S, as reported by MarketBeat.com.

Dicerna Pharmaceuticals currently has a consensus target price of $39.1429, indicating a potential upside of 33.46%. Ascendis Pharma A/S has a consensus target price of $187.6667, indicating a potential upside of 52.69%. Given Ascendis Pharma A/S's higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Dicerna Pharmaceuticals.

Summary

Dicerna Pharmaceuticals beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks.